Answer to Written Question: Vaccines

(Source: European Parliament)

EN

E-000781/2021

Answer given by Ms Kyriakides

on behalf of the European Commission

(10.9.2021)

The advance purchase agreements contain binding provisions concerning both the number of vaccine doses to be delivered and the timing of deliveries. It is essential that the companies fulfil their legal obligations.

The companies retain flexibility in the organisation of their supply chain but this cannot be a legitimate reason for a delay in a contract signed between the EU and a vaccine manufacturer. The court case against AstraZeneca has shown that the contract provisions allow for their enforcement[1] [2].

Vaccine production is a highly complex process, which requires adequate facilities, trained personnel, raw materials and other inputs. In the last months, the vaccine sector has considerably scaled up its manufacturing capacity in the EU. This allows the Commission to seek supply security through contracts that privilege production in the EU.


[1] https://ec.europa.eu/commission/presscorner/detail/en/IP_21_3090

[2] https://ec.europa.eu/commission/presscorner/detail/en/qanda_21_3107

%d bloggers like this: